Acumen Pharmaceuticals, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 16 →InsidersNo open-market buys. 9 insiders sold $625,712, 4 of 48 sales on a 10b5-1 plan.→HoldersRa 29.0%Sands Capital Alternatives 5.1%BlackRock 3.4%→Financing →PeersClosest companies: ALEC, NUVB, PRAX→
From the filings
Figures
- Net income
- −$105.0Mlast 12 months
- Operating cash flow
- −$105.5Mlast 12 months
- Cash and equivalents
- $59.4Mat the last balance sheet
- Total debt
- $31.6Mat the last balance sheet
- Shares outstanding
- 72.3M shareson issue